FOXO4-DRI vs Epithalon
FOXO4-DRI has senescent-cell and organ findings in experimental models; Epithalon has telomere-related findings in cultured cells. Neither set of findings establishes a human longevity benefit or clinical safety.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
FOXO4-DRI
Dossier overview
Epithalon
Dossier overview
What each experiment addresses
| Question | FOXO4-DRI | Epithalon (Epitalon, AEDG) |
|---|---|---|
| Proposed action | Interferes with FOXO4-p53 signaling associated with survival of some senescent cells | Alters telomerase- and telomere-related measures in cultured cells |
| Direct evidence cited here | Cell and mouse experiments, including selected fitness, fur and renal endpoints | Cultured human fetal fibroblasts and later normal and cancer cell lines |
| Human longevity outcome | Not established | Not established |
| Human safety | Not established | Not established |
FOXO4-DRI was tested in senescent-cell systems and in naturally aged or accelerated-aging mice. Baar and colleagues reported senescent-cell apoptosis and selected mouse fitness, fur and renal changes in Cell in 2017. Those outcomes do not measure longer human life or demonstrate selective clearance throughout a person’s body. Baar et al., 2017
Epithalon is a four-amino-acid peptide (AEDG). A 2003 study reported telomerase activity and telomere elongation after adding it to cultured human fetal fibroblasts. A 2025 study reported telomere-related changes in normal and breast-cancer cell lines, with different pathway readouts. A published correction replaced incorrect Figures 1–3 in that paper, so the corrected figures are part of interpreting its results. Human-derived cell lines do not establish an effect on telomeres, aging or lifespan in people. Khavinson et al., 2003 · Al-Dulaimi et al., 2025 · Correction, 2025
What the contrast does not show
The mechanisms are different, but the available experiments do not rank these peptides for human anti-aging use. A separate pulmonary-hypertension mouse study included FOXO4-DRI among senescent-cell removal interventions and reported worse pulmonary measures in its disease model. This is a model-specific adverse signal, not a quantified human risk; it also rules out a blanket assumption that senescent-cell clearance is beneficial in every context. Born et al., 2023
Neither paper set establishes the safety or benefit of using the two peptides together. Evidence for human longevity outcomes is very low for each. This comparison describes research and is not medical advice or guidance for self-treatment.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.